Wealth Alliance Advisory Group’s TG Therapeutics TGTX Stock Holding History

Wealth Alliance Advisory Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$231K	Buy	+4,200	New	+$172K	0.03%	185

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Wealth Alliance Advisory Group's TGTX Position: Q2 2026 in Review

Wealth Alliance Advisory Group opened a new position in TG Therapeutics (TGTX) in Q2 2026: 4,200 shares worth $231K. The stake represents 0.03% of the portfolio and ranks #185 among its holdings.

427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Wealth Alliance Advisory Group held 4,200 shares of TG Therapeutics worth $231K as of Q2 2026.
TG Therapeutics was a new Wealth Alliance Advisory Group position in Q2 2026.
TG Therapeutics made up 0.03% of Wealth Alliance Advisory Group's portfolio in Q2 2026, its #185 holding.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Wealth Alliance Advisory Group's 13F filing for Q2 2026, filed 23 Jul 2026.